Nanohale AG (FYB) | Finanzwire

Basculer en Français

8301	Companies
115073	Keywords
55420	Articles
62512	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 09/17/2024 at 06:55, 2 months 4 days ago

Formycon to Present FYB202 Biosimilar Data at EADV Congress and UEG Week

Clinical Data Biosimilar Formycon FYB202 Ustekinumab
PRESS RELEASE

published on 09/17/2024 at 06:50, 2 months 4 days ago

Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Formycon to present clinical data on ustekinumab biosimilar FYB202 at EADV Congress in Amsterdam and UEG Week in Vienna. Biosimilar for psoriasis and IBD in final approval phase

Clinical Data Biosimilar Formycon Ustekinumab Approval Process
BRIEF

published on 08/19/2024 at 14:16, 3 months 2 days ago

First Berlin Equity Research Maintains Buy Rating for Formycon AG

BUY Rating Biosimilars Formycon Revenue Update H1/24 Results
PRESS RELEASE

published on 08/19/2024 at 14:11, 3 months 2 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG (ISIN: DE000A1EWVY8) with H1/24 results, maintaining BUY rating and EUR 80 target price. Formycon raises FY/24 guidance due to stronger than expected results

First Berlin Equity Research BUY Rating Formycon AG H1/24 Results EUR 80 Target Price
BRIEF

published on 08/13/2024 at 06:55, 3 months 8 days ago

Formycon Reports Robust First Half-Year with Significant Milestones

Financial Results Biosimilars Clinical Milestones Formycon FYB201
PRESS RELEASE

published on 08/13/2024 at 06:50, 3 months 8 days ago

Formycon reports a strong first half-year with multiple milestones achieved
Formycon AG reports successful first half-year with key operational, clinical, and regulatory milestones achieved. Group revenue and EBITDA in line with expectations. Invitation to conference call today

Conference Call Revenue Formycon AG Milestones First Half-Year
BRIEF

published on 08/07/2024 at 06:55, 3 months 14 days ago

Formycon Announces Conference Call on 2024 Half-Year Results and Investor Conference Participation

Conference Call Investor Conferences Formycon AG Half-year Results Financial Outlook
PRESS RELEASE

published on 08/07/2024 at 06:50, 3 months 14 days ago

Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Formycon schedules conference call on 2024 half-year results and confirms participation in investor conferences. Details on webcast and management presentations

Financial Results Conference Call Investor Conferences Biosimilars Formycon
BRIEF

published on 08/06/2024 at 12:45, 3 months 15 days ago

Formycon AG Increases 2024 Fiscal Year Outlook

Adjusted EBITDA Working Capital Fiscal Year 2024 Formycon AG Biosimilars
PRESS RELEASE

published on 08/06/2024 at 12:40, 3 months 15 days ago

EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
Formycon AG increases its 2024 fiscal year outlook based on positive Lucentis biosimilar performance, adjusting EBITDA and working capital forecasts

Adjusted EBITDA Working Capital Formycon AG 2024 Fiscal Year Lucentis Biosimilar

Accesswire

Published on 11/21/2024 at 17:35, 38 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 43 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 43 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 2 hours 12 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 2 hours 13 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 17:58, 14 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 21 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 21 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.
Published on 11/21/2024 at 16:00, 2 hours 13 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 2 hours 31 minutes ago

Edison issues report on Murray Income Trust (MUT)

Les Echos

Published on 11/21/2024 at 06:58, 11 hours 15 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 53 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 10 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE